Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04884256 |
Recruitment Status :
Recruiting
First Posted : May 12, 2021
Last Update Posted : January 29, 2024
|
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | May 5, 2021 | ||||||||
First Posted Date ICMJE | May 12, 2021 | ||||||||
Last Update Posted Date | January 29, 2024 | ||||||||
Actual Study Start Date ICMJE | December 21, 2023 | ||||||||
Estimated Primary Completion Date | August 1, 2025 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
Change from Baseline in conjunctival hyperemia grade at Day 28 (Week 4). [ Time Frame: 1 month ] | ||||||||
Original Primary Outcome Measures ICMJE |
Incidence of treatment-emergent adverse events [ Time Frame: 1 month ] Visual acuity, biomicroscopy, intraocular pressure, ophthalmoscopy
|
||||||||
Change History | |||||||||
Current Secondary Outcome Measures ICMJE |
Change from Baseline conjunctival hyperemia digital image grade at Days 7 (Week 1) and 56 (Week 8). [ Time Frame: 2 month ] | ||||||||
Original Secondary Outcome Measures ICMJE |
Pinguecula Vascularity [ Time Frame: 1 month ] Change of the pinguecula vascularity grade from baseline (Day 1) at Week 4
|
||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula | ||||||||
Official Title ICMJE | A Phase 2 Multicenter, Randomized, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of CBT-004 Ophthalmic Emulsion in Patients With Vascularized Pinguecula | ||||||||
Brief Summary | STUDY DESIGN: Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. Duration of Treatment: 4 weeks of study treatment with 4 weeks follow-up observations. Control: Vehicle for CBT-004 (hereafter referred to as Vehicle). Masking: Subjects, Investigators, Study Monitors and the Independent Image Reading Center are all masked to the study medications. Dosage/Dose regimen: One drop of the assigned study medication will be administered in the study eye TID for 4 weeks. The study eye is defined as the qualified eye (i.e., the eye meeting the inclusion criterion for vascularized pinguecula). If both eyes are qualified, then the eye with the more severe vascularity grade at Visit 1 will be the study eye. |
||||||||
Detailed Description | Not Provided | ||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase ICMJE | Phase 2 | ||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment |
||||||||
Condition ICMJE | Pinguecula | ||||||||
Intervention ICMJE | Drug: CBT-004
Dose response study
|
||||||||
Study Arms ICMJE |
|
||||||||
Publications * | Not Provided | ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE |
75 | ||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||
Estimated Study Completion Date ICMJE | October 1, 2025 | ||||||||
Estimated Primary Completion Date | August 1, 2025 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Sex/Gender ICMJE |
|
||||||||
Ages ICMJE | 18 Years to 80 Years (Adult, Older Adult) | ||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||
Contacts ICMJE |
|
||||||||
Listed Location Countries ICMJE | United States | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT04884256 | ||||||||
Other Study ID Numbers ICMJE | CBT-CS103 | ||||||||
Has Data Monitoring Committee | Not Provided | ||||||||
U.S. FDA-regulated Product |
|
||||||||
IPD Sharing Statement ICMJE |
|
||||||||
Current Responsible Party | Cloudbreak Therapeutics, LLC | ||||||||
Original Responsible Party | Same as current | ||||||||
Current Study Sponsor ICMJE | Cloudbreak Therapeutics, LLC | ||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||
Collaborators ICMJE | Not Provided | ||||||||
Investigators ICMJE | Not Provided | ||||||||
PRS Account | Cloudbreak Therapeutics, LLC | ||||||||
Verification Date | January 2024 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |